{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:03:40Z","timestamp":1791187420046,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.vaccine.2011.08.017","type":"journal-article","created":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T16:56:30Z","timestamp":1312908990000},"page":"7572-7575","source":"Crossref","is-referenced-by-count":13,"title":["Registration of influenza vaccines for children in Europe"],"prefix":"10.1016","volume":"29","author":[{"given":"Marta","family":"Granstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albertha C.G.","family":"Voordouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.08.017_bib0005","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.vaccine.2009.09.138","article-title":"Evaluation of serological trials submitted for annual re-licensure of influenza vaccines to regulatory authorities between 1992 and 2002","volume":"28","author":"Voordouw","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0010","unstructured":"European Medicines Agency. Note for guidance on harmonisation of requirements for influenza vaccines (CHMP\/BWP\/214\/96)."},{"key":"10.1016\/j.vaccine.2011.08.017_bib0015","unstructured":"European Medicines Agency. Guideline on dossier structure and content for pandemic influenza marketing authorisation application (EMEA\/CHMP\/VEG\/4717\/2003)."},{"key":"10.1016\/j.vaccine.2011.08.017_bib0020","unstructured":"European Medicines Agency. Guideline on submission of marketing authorisation applications for pandemic influenza vaccines through the centralised procedure (EMEA\/CPMP\/4986\/03)."},{"key":"10.1016\/j.vaccine.2011.08.017_bib0025","unstructured":"European Medicines Agency. Guideline on Influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (CHMP\/VWP\/263499\/06)."},{"key":"10.1016\/j.vaccine.2011.08.017_bib0030","unstructured":"European Medicines Agency. European public assessment report (EPAR) for Fluenz (live, attenuated nasal influenza vaccine) (EMA\/CHMP\/682933\/2010)."},{"key":"10.1016\/j.vaccine.2011.08.017_bib0035","unstructured":"World Health Organisation. WHO recommendations to assure the quality, safety, and efficacy of influenza vaccines (human, live attenuated) for intranasal administration (WHO\/BS\/09.2111)."},{"key":"10.1016\/j.vaccine.2011.08.017_bib0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00228-011-0997-4","article-title":"Three years of paediatric regulation in the European Union","volume":"67","author":"Olski","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0040","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(05)71000-X","article-title":"Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review","volume":"365","author":"Jefferson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0045","first-page":"1","article-title":"Vaccines preventing influenza in healthy children (review)","author":"Smith","year":"2008","journal-title":"Cochrane Libr"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0050","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1086\/315820","article-title":"Studies of the 1996\u20131997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness","volume":"182","author":"Hurwitz","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0055","unstructured":"European Centre for Disease Prevention and Control. Infant and children seasonal immunisation against influenza on a routine basis during inter-pandemic period ECDC Technical Report 2007;1."},{"key":"10.1016\/j.vaccine.2011.08.017_bib0060","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/archpedi.1983.02140330006003","article-title":"Clinical reactions and antibody responses to influenza vaccines. A comparison of split or subunit vaccines in children and young adults","volume":"137","author":"Bernstein","year":"1983","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0065","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/JCM.1.6.491-494.1975","article-title":"Hemolysis-in-gel test for the demonstration of antibodies to rubella virus","volume":"1","author":"Strannegard","year":"1975","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0070","first-page":"521","article-title":"Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0075","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1016\/j.vaccine.2007.02.039","article-title":"Comparison of neutralising antibody assays for detection of antibody to influenza A\/H3N2 viruses: an international collaborative study","volume":"25","author":"Stephenson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0080","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1128\/JCM.22.6.1050-1052.1985","article-title":"Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay","volume":"22","author":"Anderson","year":"1985","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1128\/JCM.26.2.333-337.1988","article-title":"Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection","volume":"26","author":"Harmon","year":"1988","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0090","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcv.2009.09.013","article-title":"Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses","volume":"46","author":"Li","year":"2009","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0095","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1128\/JCM.12.3.426-432.1980","article-title":"Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement","volume":"12","author":"Frank","year":"1980","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0100","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1086\/315323","article-title":"Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine","volume":"181","author":"Belshe","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0105","doi-asserted-by":"crossref","first-page":"11950","DOI":"10.1128\/JVI.01305-10","article-title":"A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys","volume":"84","author":"Min","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0110","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1017\/S0022172400022610","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J Hygiene"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0115","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJM197206222862502","article-title":"Association of serum anti-neuraminidase antibody with resistance to influenza in man","volume":"286","author":"Murphy","year":"1972","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0120","first-page":"593","article-title":"A comparative study of attenuated influenza viruses","volume":"44","author":"Beare","year":"1971","journal-title":"Bull World Health Org"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1086\/518939","article-title":"Enders lecture 2006: antivirals for influenza","volume":"196","author":"Ong","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/00039896.1970.10667243","article-title":"Antibody response to influenza enzyme in man","volume":"21","author":"Davenport","year":"1972","journal-title":"Arch Environ Health"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0135","unstructured":"European Medicines Agency. Scientific workshop on serology assays and correlates of protection for influenza vaccines. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/events\/2010\/12\/event_detail_000371.jsp&murl=menus\/news_and_events\/news_and_events.jsp&mid=WC0b01ac058004d5c3 (29\/06\/2010\u201330\/06\/2010)."},{"key":"10.1016\/j.vaccine.2011.08.017_bib0140","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1016\/j.vaccine.2010.06.075","article-title":"Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences","volume":"28","author":"Gravel","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.017_bib0145","unstructured":"European Medicines Agency. Note for guidance on clinical evaluation of new vaccines (CHMP\/EWP\/463\/97)."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11012266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11012266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T04:51:30Z","timestamp":1592801490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11012266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":30,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0264410X11012266"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.08.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}